

PRESS RELEASE

Annual Report 2013 Active Biotech AB (publ)

Active Biotech's Annual Report 2013 (in Swedish) is now available for download at www.activebiotech.com. The English version will be available within short.

The Annual Report will only be digitally distributed.

Lund, April 7, 2014
Active Biotech AB (publ)

Tomas Leanderson
President & CEO

For further information, please contact:

Hans Kolam
CFO
Tel +46 (0)46 19 20 44

Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod (Nerventra[®]), an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, tasquinimod for prostate cancer and ANYARA primarily for the treatment of renal cell cancer. In addition, laquinimod Phase II clinical trials in Crohn's and Lupus has been concluded. The company also has one additional project in clinical development, the orally administered compound paquinimod (57-57) for systemic sclerosis. Please visit www.activebiotech.com for more information.

Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00

Active Biotech is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 10:00 a.m. CET on April 7, 2014.